Gaucher's disease type III
Conditions
Interventions
Drug: Venglustat
tablet
oral
Drug: imiglucerase
sterile lyophilized product
intravenous, Other Name: Cerezyme
Sponsors
Tanaka Tomoyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - The participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 3 years prior to enrollment, on a stable dose for at least 6 months, is deemed clinically stable for at least 1 year by the Investigator and is within the therapeutic goals as all of the following: - - Hemoglobin level of >=11.0 g/dL for females and >=12.0 g/dL for males - - Platelet count >=100 000/mm^3 - - Spleen volume =18 years of age - Pediatric participant is >=12 years =30 kg of weight - Contraception for sexually active male or female participants; not pregnant or breastfeeding; no sperm donating for male participant - Signed written informed assent/consent
Exclusion criteria
Exclusion criteria: Participants are excluded from the study if any of the following criteria apply: - The participant is blood transfusion-dependent. - Prior esophageal varices or liver infarction or current liver enzymes (alanine aminotransferase [ALT]/ aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal, unless the participant has a diagnosis of Gilbert Syndrome. - The participant has any clinically significant disease, other than GD, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation in the opinion of the Investigator. - The participant has renal insufficiency, as defined by an estimated glomerular filtration rate <30 mL/min/1.73m^2 at the screening visit. - The participant has a history of cancer, except for basal cell carcinoma. - The participant has progressive myoclonic epilepsy. - The participant is pregnant (has a positive serum beta-human chronic gonadotropin [beta-hCG]) or lactating. - The participant requires use of invasive ventilatory support. - The participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily. - The participant is scheduled for in-patient hospitalization including elective surgery, during the study. - The participant has had a major organ transplant (eg, bone marrow or liver). - A history of drug and/or alcohol abuse within the past year prior to the screening visit. - Chaperone therapy within 6 months, substrate reduction therapy other than venglustat within 6 months or venglustat substrate reduction therapy prior to enrollment. - Exposure to any investigational drug (including venglustat) within the last 30 days or 5 half-lives from screening, whichever is longer. - The participant has received strong or moderate inducers or inhibitors of CYP3A within 14 days or 5 half-lives from screening, whichever is longer, prior to screening. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat. The participant is unwilling to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for the duration of the treatment period. - The participant, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (eg, contraindication for MRI). - Type of participant and disease characteristic: the participant has had a total splenectomy prior to enrollment. The patient had a partial splenectomy within 3 years prior to randomization. - Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures. - Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Change in Scale for Assessment and Rating of Ataxia (SARA) modified total score [Time Frame baseline:From baseline to Week 52] 2.Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score [Time Frame baseline:From baseline to Week 52] | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Percent change in spleen volume [Time Frame: From baseline to Week 52] 2.Percent change in liver volume [Time Frame: From baseline to Week 52] 3.Change in hemoglobin level [Time Frame: From baseline to Week 52] 4.Percent change in platelet count [Time Frame: From baseline to Week 52] 5. Percent change in CSF GL-1 and lyso-GL-1 levels [Time Frame baseline: From baseline to Week 52] 6. Percent change in plasma GL-1 and lyso-GL-1 levels [Time Frame baseline: From baseline to Week 52] 7.Number of patients with treatment emergent adverse events (TEAEs)/ serious adverse events (SAEs)/ adverse events of special interest (AESIs) [Time Frame: From baseline to max of 3.5 years] 8.Change in score of Beck Depression Inventory II (BDI-II) during the treatment-emergent period (for participants 13 years of age and above at baseline) [Time Frame: From baseline to Week 52] 9.Change in Patient Health Questionnaire 9 (PHQ-9) during the treatment-emergent period (for participants 12 years of age at baseline) [Time Frame: From baseline to Week 52] | — |
Countries
Argentina, Canada, China, France, Germany, Hungary, Italy, Japan, Turkey, United Kingdom, United States
Contacts
Public ContactUnit Clinical
Sanofi K.K.
Outcome results
None listed